4DMT un­veils dose ex­plo­ration da­ta in wet AMD; Ex­i­cure in­stalls new C-suite ex­ec

4D Mol­e­c­u­lar Ther­a­peu­tics has some new da­ta from a Phase I/II tri­al test­ing a wet AMD can­di­date in dif­fer­ent dose lev­els.

The biotech re­port­ed Thurs­day in­ter­im da­ta from three dos­es of ge­net­ic med­i­cine can­di­date 4D-150 in 15 pa­tients, de­liv­ered in­trav­it­re­al­ly. Be­yond all the dos­es be­ing well-tol­er­at­ed, 4D said that all three dos­es showed “clin­i­cal ac­tiv­i­ty,” which in­clud­ed met­rics such as sta­ble vi­su­al acu­ity and “sta­ble or im­proved reti­nal ede­ma and thick­ness.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.